Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28Neoplasm Metastasis 6Recurrence 5Breast Neoplasms 4Stomach Neoplasms 3Prostate Cancer Metastatic 3Neoplastic Cells, Circulating 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer, Hereditary, 7 1Penile Neoplasms 1Nonseminomatous germ cell tumor 1Metastatic Castration-resistant Prostate Cancer, MCRPC 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Breast Cancer With Intracranial Metastases 1Lung Neoplasms 1Liposarcoma 1Hormone-Resistant Prostate Cancer 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Diarrhea 1

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone-Resistant Prostate Cancer × cabazitaxel × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡